Companies
Jeevam Health (YC S20) is a healthcare app for holistic thyroid treatment.. Even after taking medication, 60% of women are having unresolved symptoms like fatigue, weight issues, and pregnancy challenges. Jeevam software assists doctors to diagnose the root cause of dysfunctions & recommend treatment protocol. The treatment revolves around nutrition, supplements, lifestyle changes, and medicine.
Joon is an integrated pediatric digital health platform for kids, starting with behavior disorders like ADHD, autism, anxiety, and depression. In Joon, kids access a game-based digital therapeutic where they level up when they do real-life behaviors that are managed by parents and clinicians. Over the next 10 years, we plan on being the first-line vertically integrated digital treatment for pediatric behavior disorders, leveraging the first of its kind technology to drive behavior change.
Junction is an API for at-home health data that makes it easy for health tech companies to collect data from 100's of wearable devices and deliver at-home test kits to their users. Healthtech companies need lab data as well as wearable data, and we give them access to both through a single line of code.
Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.
Kaigo Health provides an AI-powered outpatient care management platform that automates and scales remote care management for Medicare patients including post-discharge followups, ongoing check-ins, and monitoring. Using phone calls as an age-friendly interface, we aggregate patient responses, voice biomarkers, and remote patient monitoring data for powerful preventative and proactive healthcare.
KemNet supplies pharmacies with premium reformulations of popular drugs that are more useful for specific groups of patients. For example, more than 30 pharmacies rely on KemNet to supply reformulated products for erectile dysfunction that work up to 8 times faster than alternatives. In addition to sexual function, products reformulated for novel drug delivery and supplied on KemNet include medications for hair growth, pain, weight loss and women's health.
DNA has emerged as a compelling data storage medium due to its density, longevity, and eternal relevance compared to current memory technologies. However, the high price of synthesizing DNA remains a major bottleneck for adoption of this promising storage solution. We are pioneering new approaches to synthesizing DNA for data storage with enzymes and custom digital codecs. We are building an interdisciplinary team to build the world's most scalable information infrastructure in DNA. We seek technical experts in enzyme engineering, chemistry, hardware engineering, and information theory. We also seek business development to identify emerging markets for early use cases of our technology.
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
We combined microfluidic chip technology and a reagent cartridge to create the first personal DNA synthesizer. Until now most life scientists had to rely on out-sourced DNA synthesis, causing stagnating research. Kilobaser empowers every life scientist to synthesize DNA on their benchtop.
Kingdom creates and sells Superculture® ingredients. Our Superculture® ingredients are an entirely new class of clinically-validated postbiotics that target the root causes of unmet pet health needs. Superculture® Pet Oral and Superculture® Pet Immune are our first two breakthrough ingredients, driving industry-leading efficacy and unlocking new marketing claims for brands.
Kip combines traditional in-person therapy with a private app so that you get the most out of every session. Meet your therapist in person and start working on your personalized care plan. Share daily thoughts, feelings, and events with your therapist on Kip's private app. Achieve measurable results with Kip's science-backed, results-driven approach. Not your average therapy service, Kip makes therapy more effective by combining in-person visits with digital support in-between.
Kips Health
The only patient engagement software that pays you.
Kips Health enables physical therapists to automatically collect RTM reimbursements with only 5 minutes of work.
Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.
Fully-automated Quantitative MR Image Analysis. Our software converts a user’s full body magnetic resonance scan (MRI) into a 3D virtual model of their body in the cloud. The model is annotated with explanatory information so they can easily explore and learn about different parts of their body. Klarismo is the only provider of MR analytics that can offer truly scalable analysis for large data collections. Cloud-based processing allows 1000s of acquisitions to be analyzed simultaneously. Machine learning techniques utilize Klarismo’s proprietary collection of labelled MRI data and eliminate the need for manual processing to produce precise volumetric measurements. Klarismo specializes in the detailed analysis of body composition, including volumetric measurements of different muscle and fat tissues, from whole-body acquisitions.
Known Medicine combines patient-specific 3D cell culture & AI to translate drugs to clinical success. We receive patient tumors, break them down, make thousands of micro-tumors, and then treat each with different drugs to determine which they will respond best to.
We’re on a mission to leverage AI and voice technology to solve inefficiencies and revenue leakage in our healthcare system. With the rise of EHRs, the manual documentation burden on doctors has never been higher, leading to burnout and fatigue and high attrition rates. Assigning the correct diagnosis and billing codes is crucial for proper reimbursement and patient care, but medical coding is becoming more and more complex each year with growing numbers of codes (over 145,000 now), and doctors are unsupported by current technology to keep up with its ever increasing requirements. $125 billion is left on the table each year by healthcare organizations due to improper documentation and coding. Knowtex creates visit notes with up-to-date and accurate reimbursement codes from doctor-patient conversations, allowing the doctor to focus on patient care and preventing revenue leakage for hospital systems through standardized, transparent, and accurate documentation.
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective "full stack" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.
